Form 4: Amneal Pharmaceuticals Director Acquires Shares Through Restricted Stock Unit Vesting
SEC Form 4
Director Jeffrey P. George acquired 40,258 shares of Amneal Pharmaceuticals Class A Common Stock through the vesting of restricted stock units on May 5, 2025.
Summary
- On May 5, 2025, Jeffrey P. George, a director of Amneal Pharmaceuticals, acquired 40,258 shares of Class A Common Stock due to the vesting of restricted stock units.
- Following this transaction, Mr. George directly owns 309,795 shares of Class A Common Stock.
- Additionally, Mr. George was granted 34,819 restricted stock units on May 6, 2025, which will vest on the later of the day immediately preceding the issuer's first annual meeting of the stockholders following the date of grant and the day immediately following the first anniversary of the date of grant.
- These new restricted stock units bring his total holdings of unvested restricted stock units to 34,819.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It reflects a standard transaction related to executive compensation. The director's increased stake could be viewed positively, but it's a routine event.
Positives
- The acquisition of shares by a director can be seen as a positive signal, indicating confidence in the company's future prospects.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's financial performance or future outlook.
Industry Context
This filing is a routine disclosure related to insider transactions and provides insight into the holdings of a key company director. It's common for executives and directors to receive stock-based compensation, and these filings are a standard part of regulatory compliance.
Stakeholder Impact
- Shareholders may view the director's increased stake as a positive sign of confidence in the company.
- Employees may see this as a reflection of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 05/02/2024 | Reporting person was granted 40,258 restricted stock units vesting on May 5, 2025. |
| 05/05/2025 | 40,258 restricted stock units vested, resulting in the acquisition of Class A Common Stock. |
| 05/06/2025 | 34,819 restricted stock units were granted, vesting on the later of the day immediately preceding the issuer's first annual meeting of the stockholders following the date of grant and the day immediately following the first anniversary of the date of grant. |
| 05/08/2025 | Date of signature on the SEC Form 4 filing. |
Keywords
Amneal Pharmaceuticals, Director, Jeffrey P. George, AMRX, Restricted Stock Units, Class A Common Stock, Beneficial Ownership, SEC Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.